<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Metformin poisoning</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Metformin poisoning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Metformin poisoning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jason Chu, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Stolbach, MD, MPH, FAACT, FACMT, FACEP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert G Hendrickson, MD, FACMT, FAACT</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In normal individuals, fasting plasma glucose levels range from about 60 to 100 mg/dL (3.3 to 5.6 mmol/L) [<a href="#rid1">1</a>]. In patients with diabetes mellitus, insulin deficiency or insulin resistance leads to a state of hyperglycemia. Galega officinalis (goat's rue or French lilac) was used to treat diabetes in medieval Europe. The active ingredient, guanidine, was used to synthesize other antidiabetic agents in the 1920s [<a href="#rid2">2</a>], and the biguanide hypoglycemic agents phenformin and <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> became available for clinical use in the 1950s.</p><p>Biguanides are antihyperglycemic agents, not hypoglycemic agents; they promote euglycemia but alone are unlikely to cause hypoglycemia. Biguanides are used both as monotherapy and in combination with other oral hypoglycemic agents. They can exacerbate hypoglycemia caused by other types of antidiabetic medicines [<a href="#rid3">3,4</a>].</p><p>The major toxicity from acute or chronic biguanide use is lactic acidosis. The high rate of severe lactic acidosis from phenformin led to the withdrawal of this drug from the US market in 1976, although it remains available in several countries. <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> is the principal biguanide in clinical use.</p><p>The management of <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> toxicity is reviewed here. A summary table to facilitate emergent management is provided  (<a class="graphic graphic_table graphicRef68482" href="/d/graphic/68482.html" rel="external">table 1</a>). General issues relating to hypoglycemia, the therapeutic use of biguanides, and the general clinical management of drug intoxication are presented separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1808.html" rel="external">"Physiologic response to hypoglycemia in healthy individuals and patients with diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1798.html" rel="external">"Hypoglycemia in adults without diabetes mellitus: Determining the etiology"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1809.html" rel="external">"Metformin in the treatment of adults with type 2 diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PHARMACOLOGY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> decreases insulin resistance, decreases hepatic glucose output, and enhances peripheral glucose uptake [<a href="#rid5">5</a>]. Proposed mechanisms of action include enhanced suppression of gluconeogenesis by insulin, reduced glucagon-stimulated gluconeogenesis, and increased uptake of glucose by muscle and adipose cells [<a href="#rid5">5</a>]. The net effects of these changes in diabetic patients are to decrease fasting and post-prandial blood glucose by 20 to 40 percent, decrease hemoglobin A1C, decrease body weight slightly, decrease low density lipoprotein (LDL), and increase high density lipoprotein (HDL) [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/1809.html" rel="external">"Metformin in the treatment of adults with type 2 diabetes mellitus"</a>.) </p><p class="headingAnchor" id="H3"><span class="h1">KINETICS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> absorption occurs primarily in the upper part of the intestine [<a href="#rid7">7</a>]. The drug has negligible plasma protein binding and a volume of distribution ranging from 63 to 276 L (1 to 5 L/kg) [<a href="#rid6">6-8</a>]. The elimination half-life of metformin in patients who take multiple doses and have good renal function is approximately five hours [<a href="#rid7">7</a>]. Metformin is excreted, unmetabolized, via transporters in the proximal tubules of the kidneys, and may accumulate in acute and chronic kidney disease [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H1630281887"><span class="h1">CLINICAL FEATURES OF TOXICITY</span></p><p class="headingAnchor" id="H2507016636"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>Patients with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> overdose may complain of nausea and abdominal pain [<a href="#rid10">10-12</a>]. In the setting of chronic metformin use and lactic acidosis accumulation (metformin-associated lactic acidosis [MALA]), the most common complaints are gastrointestinal (including nausea, vomiting, and diarrhea) followed by altered mental status and shortness of breath [<a href="#rid13">13</a>]. </p><p>Physical examination findings may include tachycardia, hypotension, and tachypnea in patients with severe lactic acidosis. Alterations in mental status may be due to acidosis or hypoglycemia [<a href="#rid10">10-12</a>], although the latter is uncommon without concurrent use of a hypoglycemic agent.</p><p class="headingAnchor" id="H4"><span class="h2">Lactic acidosis</span></p><p class="headingAnchor" id="H4178357057"><span class="h3">Incidence</span><span class="headingEndMark"> — </span>MALA may occur following acute overdose [<a href="#rid10">10,11,14-17</a>]. A United Kingdom poison control center study that included 117 patients with isolated <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> overdose found that 28 percent developed a lactic acidosis [<a href="#rid18">18</a>]. MALA may also develop in patients with comorbidities such as kidney or hepatic insufficiency or a precipitating disease (eg, acute infection), leading to acute kidney injury and impaired metformin elimination. Otherwise, MALA is unlikely to occur. A systematic review of 347 trials and cohort studies revealed no cases of fatal or nonfatal lactic acidosis in 47,846 patient-years of metformin use and calculated the upper limit of the incidence of such lactic acidosis to be 4.3 cases per 100,000 patient years [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/d/html/2370.html" rel="external">"Causes of lactic acidosis", section on 'Diabetes mellitus'</a>.)</p><p class="headingAnchor" id="H3600357996"><span class="h3">Mechanism</span><span class="headingEndMark"> — </span>The mechanism of MALA is complex. <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> promotes the conversion of glucose to lactate in the splanchnic bed of the small intestine [<a href="#rid20">20</a>]. Metformin also inhibits mitochondrial respiratory chain complex 1, leading to decreased hepatic gluconeogenesis from lactate, pyruvate, and alanine [<a href="#rid13">13</a>]. This results in additional lactate and substrate for lactate production [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H399028504"><span class="h3">Risk factors</span><span class="headingEndMark"> — </span>Because reports of dosages in overdose are often unreliable, it is unclear what minimum dose of <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> leads to toxicity. The clinician should have a high index of suspicion for toxicity in children who ingest more than one or two tablets, anyone who presents with intentional overdose, and patients with comorbidities such as acute or chronic kidney disease, liver disease, or heart failure.</p><p>Clinically significant lactic acid accumulation almost always occurs in the presence of comorbid conditions, such as the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Impaired kidney function (precise thresholds vary; details are provided separately) [<a href="#rid22">22</a>] (see  <a class="medical medical_review" href="/d/html/1809.html" rel="external">"Metformin in the treatment of adults with type 2 diabetes mellitus", section on 'Contraindications'</a>))</p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent liver disease </p><p class="bulletIndent1"><span class="glyph">●</span>Active alcohol use</p><p class="bulletIndent1"><span class="glyph">●</span>Unstable or acute heart failure</p><p class="bulletIndent1"><span class="glyph">●</span>History of lactic acidosis during <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased tissue perfusion or hemodynamic instability</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoxic states or serious acute illness</p><p></p><p class="headingAnchor" id="H3420500692"><span class="h3">Outcomes</span><span class="headingEndMark"> — </span>Mortality is high in patients with MALA. A metanalysis (44 studies, 170 cases) found a mortality of 36 percent [<a href="#rid23">23</a>]. Similarly high mortality has been reported in multiple case series [<a href="#rid13">13,24-26</a>].  </p><p>In patients with MALA from a precipitating disease, neither arterial lactate levels nor plasma <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> concentrations predict mortality. Death more closely correlates with underlying acute or comorbid conditions. In a case series of 66 patients with MALA, the absolute metformin and lactate concentrations were not different in survivors and non-survivors [<a href="#rid13">13</a>]. Multiple organ dysfunction, such as liver dysfunction as demonstrated by an elevated prothrombin time, has been found to predict mortality in patients with MALA [<a href="#rid25">25</a>].</p><p>In patients with MALA from confirmed acute <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> overdose, a systematic review found that lower serum pH and higher serum lactate concentrations correlated with increased mortality [<a href="#rid27">27</a>]. All 16 survivors had a serum pH above 6.9 and a serum lactate below 25 mmol/L, while 5 of the 6 patients with a pH less than 6.9 or a lactate greater than 25 mmol/L died. The United Kingdom poison center study found that the degree of toxicity correlated with the serum lactate concentration and inversely correlated with the arterial pH. These laboratory values did not correlate with each other, and either could be an independent marker of poisoning severity [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H3376862991"><span class="h2">Hypoglycemia</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> can contribute to hypoglycemia when in combination with other hypoglycemic drugs but is alone unlikely to cause hypoglycemia [<a href="#rid3">3,4</a>].</p><p class="headingAnchor" id="H7"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H2411644163"><span class="h2">History</span><span class="headingEndMark"> — </span>In the setting of acute overdose, clinicians should seek information about dose and co-ingestants, although such information is frequently unreliable. Whether the patient has an acute overdose or chronic toxicity, clinicians should also ask whether other antidiabetic agents are used.</p><p class="headingAnchor" id="H27562396"><span class="h2">Studies to obtain</span><span class="headingEndMark"> — </span>Routine evaluation of any acutely poisoned patient should include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status; this is particularly important in patients in whom <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> toxicity is suspected, and in diabetics generally</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">Acetaminophen</a> and salicylate levels, to rule out these common co-ingestions</p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram, to rule out conduction system poisoning by co-ingestants that affect the QRS or QTc intervals</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy test in women of childbearing age</p><p></p><p>Specific laboratory testing in cases of known or suspected <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> toxicity should include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Arterial or venous blood gas, for accurate determination of the patient's acid-base status</p><p class="bulletIndent1"><span class="glyph">●</span>Basic chemistries, to determine the bicarbonate concentration and to assess kidney function</p><p class="bulletIndent1"><span class="glyph">●</span>Serum lactate level, to confirm that any metabolic acidosis is in fact a lactic acidosis</p><p></p><p class="headingAnchor" id="H27562403"><span class="h2">Role of metformin concentration</span><span class="headingEndMark"> — </span>Obtaining a serum <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> concentration is unhelpful in most cases because few hospitals perform the test and thus timely results are rarely available, and because the serum concentration often does not correlate with the severity of the poisoning or patient outcome [<a href="#rid13">13,24,27,28</a>]. An undetectable concentration excludes metformin as the cause of lactic acidosis in most cases. Nevertheless, it is important to consider other causes of lactic acidosis (eg, sepsis, bowel ischemia) in patients who take metformin.</p><p class="headingAnchor" id="H668756836"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> overdose is diagnosed by history of intentional metformin ingestion. Metformin-associated lactic acidosis (MALA) is diagnosed with an elevated serum lactate concentration in conjunction with taking metformin. </p><p>The priority in diagnosis is identifying the presence of lactic acidosis and any precipitating illnesses. Distinguishing whether <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> is causing or contributing to the acidosis and clinical picture does not alter management. Therefore, while some authors use the term "metformin-induced" lactic acidosis (rather than "metformin-associated") to distinguish the condition where metformin is clearly responsible, making this distinction may require obtaining a metformin concentration, which is not readily available [<a href="#rid26">26</a>].</p><p>An extremely elevated lactate concentrations suggests that <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> is contributing to the clinical presentation. For example, a retrospective study of emergency department patients with suspected sepsis-induced lactic acidosis found that patients with MALA had much higher lactate concentrations (14.7 versus 5.9 mmol/L) [<a href="#rid29">29</a>]. The combined parameters of lactate &gt;8.4 mmol/L, creatinine &gt;2.9 mg/dL, and history of metformin use had a specificity of 99 percent for MALA in patients with suspected sepsis-induced lactic acidosis.</p><p class="headingAnchor" id="H8"><span class="h1">MANAGEMENT OF OVERDOSE OR TOXICITY</span><span class="headingEndMark"> — </span>The following treatment recommendations are based upon our clinical experience and the limited available evidence. A summary table to facilitate emergent management is provided  (<a class="graphic graphic_table graphicRef68482" href="/d/graphic/68482.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H9"><span class="h2">Airway, breathing, circulation</span><span class="headingEndMark"> — </span>Patients with acute or chronic <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> toxicity rarely require endotracheal intubation. It is important to note that hyperpnea and tachypnea may reflect compensation for a metabolic acidosis and may not represent impending respiratory failure. If intubation is required, the clinician should pay special attention to ventilator management. Minute ventilation sufficient to compensate for any underlying acidosis should be maintained and arterial blood gas results checked frequently until the patient is stabilized. (See  <a class="medical medical_review" href="/d/html/2352.html" rel="external">"Simple and mixed acid-base disorders"</a>.)</p><p>Hypotension should initially be treated with intravenous fluids, followed by vasopressors if needed. Persistent hypotension suggests profound toxicity, and in such cases hemodialysis treatment is often necessary. (See <a class="local">'Extracorporeal removal'</a> below.)</p><p class="headingAnchor" id="H10"><span class="h2">Gastrointestinal decontamination</span><span class="headingEndMark"> — </span>Gastrointestinal (GI) decontamination with activated charcoal (AC) is suggested in patients with acute <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> ingestion, unless specific contraindications (such as bowel obstruction or GI perforation) exist. Patients with toxicity from chronic use are unlikely to benefit from GI decontamination. The clinician must assess aspiration risk, including mental status and ability to protect the airway, in all patients before any attempts to administer AC. (See  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Activated charcoal'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Hypoglycemia</span><span class="headingEndMark"> — </span>If hypoglycemia is present, it should be treated with 0.5 to 1 g/kg <a class="drug drug_general" data-topicid="8711" href="/d/drug information/8711.html" rel="external">IV dextrose</a>, followed by a meal if food is not contraindicated. <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> alone should not cause hypoglycemia and other causes should be sought. The acute management of hypoglycemia in children is discussed separately. (See  <a class="medical medical_review" href="/d/html/5805.html" rel="external">"Approach to hypoglycemia in infants and children"</a>.)</p><p class="headingAnchor" id="H834426520"><span class="h2">Lactic acidosis</span></p><p class="headingAnchor" id="H12"><span class="h3">Sodium bicarbonate</span><span class="headingEndMark"> — </span>The use of <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a> in metformin-associated lactic acidosis (MALA) is controversial. If severe metabolic acidosis is present, sodium bicarbonate may be administered, but there are theoretical disadvantages to its use [<a href="#rid12">12</a>]. These disadvantages include leftward shift of the hemoglobin dissociation curve, excess sodium load, rebound metabolic alkalosis, disturbances in serum potassium and calcium, decreased myocardial contractility, increased carbon dioxide production, and reflex vasodilation after bolus injection [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/2294.html" rel="external">"Bicarbonate therapy in lactic acidosis"</a>.)</p><p>Extrapolating from other clinical scenarios, we suggest limiting the use of <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a> to patients with severe metabolic acidosis (arterial pH below 7.1, or below 7.2 in patients with severe acute kidney injury), with the aim being to maintain the pH above 7.1 (or above 7.3 in patients with severe acute kidney injury), until the acute toxicity resolves.</p><p class="headingAnchor" id="H13"><span class="h3">Extracorporeal removal</span><span class="headingEndMark"> — </span>Hemodialysis has been used successfully in patients with MALA that developed from chronic use or acute overdose [<a href="#rid8">8,12,30-32</a>]. We concur with the suggestions of the Extracorporeal Treatments in Poisoning Workgroup and recommend hemodialysis for patients with any of the following findings associated with severe <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> poisoning from chronic use or acute overdose [<a href="#rid8">8</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Severely elevated serum lactate concentration (&gt;20 mmol/L)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe metabolic acidosis (pH ≤7.0)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Failure to improve (as determined by pH, lactate concentration, or clinical status) with supportive care and bicarbonate therapy within two to four hours. </p><p></p><p>Although evidence is limited, we suggest hemodialysis for patients with any of the following findings:</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated serum lactate concentration between 15 to 20 mmol/L</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic acidosis (pH of 7.0 to 7.1)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Comorbidities:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Shock or persistent hemodynamic instability requiring vasopressor therapy despite acute administration of IV boluses of isotonic crystalloid totalling 30 mL/kg  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Kidney injury – Creatine &gt;2 mg/dL (adults), or &gt;1.5 mg/dL (elderly), or 2 times upper limit of normal (children), or chronic kidney disease (stage 3b or higher with eGFR &lt;45 mL/min/1.73 m<sup>2</sup>, oliguria, or anuria)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Liver failure – liver injury with coagulopathy (INR &gt;1.5) and any degree of encephalopathy </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decreased level of consciousness </p><p></p><p>For critically ill patients who do not meet any of the above criteria, (eg, those with lactate concentrations &gt;15 mmol/L, or pH 7.0 to 7.1 ), or who have important comorbid conditions (eg, kidney insufficiency, liver failure, decreased level of consciousness), it is important to obtain early consultation with a medical toxicologist and a nephrologist, and to coordinate care with these specialists, as such patients may progress quickly to needing hemodialysis [<a href="#rid8">8</a>]. </p><p>Hemodialysis should be performed using a bicarbonate buffer, as the benefits of hemodialysis lie in correcting the metabolic acidosis much more so than in removing <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>. Treatment may need to be repeated should metabolic derangements recur. Hemodialysis may be discontinued when the lactate concentration is &lt;3 mmol/L and the pH is &gt;7.35 [<a href="#rid8">8</a>]. </p><p>For patients with severe <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> poisoning requiring extracorporeal removal, hemodialysis is the preferred approach if the hemodynamics are adequate. Continuous hemodialysis (&gt;15 hours) has been used successfully in extremely ill patients. If the patient is hemodynamically unstable, CVVH or CVVHD should be considered. Continuous venovenous hemofiltration (CVVH) has been performed in patients with metformin overdose [<a href="#rid12">12,33</a>]. According to case reports, the clearance of drug by CVVH was less than that generally reported to occur with conventional hemodialysis [<a href="#rid30">30,33</a>]. Therefore, CVVH should only be considered in patients who are too hemodynamically unstable to tolerate hemodialysis. </p><p>Although there are no randomized trials of prolonged renal replacement therapy in severe <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> poisoning, retrospective series and case reports support this approach when necessary [<a href="#rid25">25,33-35</a>]. </p><p class="headingAnchor" id="H14"><span class="h2">No antidotal treatment</span><span class="headingEndMark"> — </span>There are no antidotes for <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> toxicity.</p><p class="headingAnchor" id="H15"><span class="h1">DISPOSITION</span><span class="headingEndMark"> — </span>The onset of lactic acidosis may take several hours, so patients reporting an acute ingestion should be observed for at least six to eight hours [<a href="#rid3">3,36</a>]. Patients who are well appearing and who have a normal acid-base status after six to eight hours may be discharged or transferred to the care of a psychiatrist.</p><p>If a patient deteriorates despite appropriate supportive care, the clinician should promptly consult nephrology regarding the possibility of hemodialysis. During this consultation, the clinician should convey to the nephrologist both the patient's clinical condition and, if available, serial acid-base determinations to help document the patient's deterioration.</p><p>Patients may present with a mild lactate elevation or mildly increased anion gap, but have normal vital signs and an unremarkable physical examination. Such patients may be discharged home with careful instructions to stop taking their <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> and to see their primary clinician within the next several days <strong>if</strong> the laboratory abnormalities are minor and resolve on repeat evaluation after a brief period (approximately six hours) of uneventful observation. Asymptomatic patients with persistent abnormalities (metabolic acidosis; elevated lactate) and symptomatic patients should be observed using the same guidelines described for acute ingestions, or they should be admitted to the hospital for observation.</p><p class="headingAnchor" id="H16"><span class="h1">PEDIATRIC CONSIDERATIONS</span><span class="headingEndMark"> — </span>The number of pediatric patients with Type II diabetes is increasing, likely as a result of the pediatric obesity epidemic. <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> is one of only a few drugs approved for the treatment of Type II diabetes in this population. It is logical to treat pediatric metformin toxicity in the same manner as one would treat adults, and anecdotal success supports such therapy [<a href="#rid37">37,38</a>]. (See  <a class="medical medical_review" href="/d/html/5821.html" rel="external">"Management of type 2 diabetes mellitus in children and adolescents"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H4033515291"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical and/or medical toxicologists available for bedside consultation and/or inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.) </p><p class="headingAnchor" id="H1923523253"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/d/html/114014.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacology and kinetics</strong> – Biguanides are antihyperglycemic agents (not hypoglycemic agents) since they promote euglycemia. <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> absorption occurs primarily in the intestine, and the drug is excreted unmetabolized from the kidneys. It may accumulate in renal failure. (See <a class="local">'Pharmacology'</a> above and <a class="local">'Kinetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features of toxicity</strong> – Signs and symptoms can include nausea and abdominal pain, and tachycardia, hypotension, tachypnea, and altered mental status in patients with severe lactic acidosis. (See <a class="local">'Clinical features of Toxicity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypoglycemia</strong> – <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> can contribute to hypoglycemia when in combination with other hypoglycemic drugs but is alone unlikely to cause hypoglycemia. (See <a class="local">'Hypoglycemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lactic acidosis</strong> – Metformin-associated metabolic acidosis (MALA) is the major toxicity of <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>. MALA may occur in patients with acute metformin overdose and those taking metformin who develop a precipitating illness that causes tissue hypoxemia or kidney injury and impaired metformin elimination. Risk factors include renal insufficiency, liver disease, alcohol use, heart failure, and history of lactic acidosis during metformin therapy. (See <a class="local">'Lactic acidosis'</a> above.)</p><p></p><p class="bulletIndent2">In patients who develop MALA from a precipitating illness, mortality correlates with the severity of the underlying medical conditions. In patients with MALA from acute <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> overdose, death correlates with high plasma lactate and low serum pH. (See <a class="local">'Outcomes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> –<strong> </strong>Routine evaluation of any acutely poisoned patient should include fingerstick glucose, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> and salicylate concentrations, electrocardiogram, and pregnancy test in females of childbearing age. Specific laboratory testing in cases of known or suspected <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> toxicity includes serum chemistries, arterial or venous blood gas, and serum lactate concentration (to confirm the metabolic acidosis is in fact a lactic acidosis). (See <a class="local">'Studies to obtain'</a> above.)</p><p></p><p class="bulletIndent1">Obtaining a serum <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> concentration is unhelpful in most cases because few hospitals perform the test, and the concentration often does not correlate with the severity of the poisoning or patient outcome. If the test is available, an undetectable concentration excludes metformin as the cause of lactic acidosis in most cases. (See <a class="local">'Role of metformin concentration'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a><strong> </strong>overdose is diagnosed by history of intentional metformin ingestion. MALA is diagnosed with an elevated serum lactate concentration in conjunction with taking metformin. The priority in diagnosis is identifying the presence of lactic acidosis and any precipitating illnesses. Distinguishing whether metformin is causing or contributing to the acidosis and clinical picture does not alter management, thus the term "metformin-associated" lactic acidosis). An extremely elevated lactate concentration (ie, &gt;8 mmol/L) suggests that metformin is contributing to the clinical presentation. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – A summary table to facilitate emergency management of <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> intoxication is provided  (<a class="graphic graphic_table graphicRef68482" href="/d/graphic/68482.html" rel="external">table 1</a>). Care is mainly supportive, with hemodialysis used to treat MALA. There is no antidote for metformin toxicity. (See <a class="local">'Management of overdose or toxicity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Supportive care</strong> – Patients with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> toxicity rarely require tracheal intubation. Hyperpnea and tachypnea may reflect compensation for a metabolic acidosis and may not represent impending respiratory failure. If intubation is required, the clinician should pay special attention to ventilator management. Minute ventilation sufficient to compensate for any underlying acidosis should be maintained and arterial blood gas results checked frequently until the patient is stabilized. Persistent hypotension suggests profound toxicity. (See <a class="local">'Airway, breathing, circulation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gastrointestinal (GI) decontamination</strong> – In patients with <strong>acute</strong> <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> ingestion, we suggest GI decontamination with activated charcoal (AC) be performed (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). AC should <strong>not</strong> be given to patients with toxicity from chronic use. The clinician must assess aspiration risk before any attempts to administer AC. (See <a class="local">'Gastrointestinal decontamination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypoglycemia</strong> – Treat hypoglycemia with dextrose 0.5 to 1 g/kg IV, followed by a meal if food is not contraindicated. (See <a class="local">'Hypoglycemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MALA</strong> – In patients with severe metabolic acidemia (ie, arterial pH less than 7.15), we suggest administering <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). A reasonable goal is to maintain the pH above 7.15 until the acute toxicity resolves. (See <a class="local">'Sodium bicarbonate'</a> above and  <a class="medical medical_review" href="/d/html/2294.html" rel="external">"Bicarbonate therapy in lactic acidosis"</a>.)</p><p></p><p class="bulletIndent2">In patients with MALA and any of the following, we <strong>recommend</strong> hemodialysis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>): </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Lactate concentrations &gt;20 mmol/L</p><p class="bulletIndent3"><span class="glyph">-</span>Severe metabolic acidosis (pH ≤7.1)</p><p class="bulletIndent3"><span class="glyph">-</span>Failure to improve within two to four hours despite appropriate supportive care and bicarbonate therapy </p><p></p><p class="bulletIndent2">In patients with MALA and any of the following, we <strong>suggest</strong> hemodialysis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Lactate concentrations between 15 to 20 mmol/L</p><p class="bulletIndent3"><span class="glyph">-</span>Metabolic acidosis with pH 7.0 to 7.1</p><p class="bulletIndent3"><span class="glyph">-</span>Presence of comorbid conditions (shock, kidney impairment, liver failure, or decreased level of consciousness)</p><p></p><p class="bulletIndent2">Hemodialysis has been used successfully in patients with MALA due to chronic use or acute overdose. Early consultation with a medical toxicologist and a nephrologist should be obtained for any patient with signs of severe toxicity, acidosis, or for when considering hemodialysis. (See <a class="local">'Extracorporeal removal'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disposition</strong> – Patients reporting an acute ingestion should be observed for at least six to eight hours. Patients who are well appearing and who have a normal acid-base status after six to eight hours may be discharged or transferred to the care of a psychiatrist. </p><p></p><p class="bulletIndent1">If a patient deteriorates during a period of observation, the clinician should promptly consult nephrology regarding the possibility of hemodialysis. Serial acid-base determinations help document the patient's deterioration. (See <a class="local">'Disposition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pediatric considerations</strong> – We treat children with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> overdose in the same manner as adults. (See <a class="local">'Pediatric considerations'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Service FJ. Hypoglycemic disorders. N Engl J Med 1995; 332:1144.</a></li><li><a class="nounderline abstract_t">Bailey CJ, Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care 1989; 12:553.</a></li><li><a class="nounderline abstract_t">Harrigan RA, Nathan MS, Beattie P. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. Ann Emerg Med 2001; 38:68.</a></li><li><a class="nounderline abstract_t">Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49:721.</a></li><li><a class="nounderline abstract_t">Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574.</a></li><li><a class="nounderline abstract_t">Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999; 20:489.</a></li><li><a class="nounderline abstract_t">Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011; 50:81.</a></li><li><a class="nounderline abstract_t">Calello DP, Liu KD, Wiegand TJ, et al. Extracorporeal Treatment for Metformin Poisoning: Systematic Review and Recommendations From the Extracorporeal Treatments in Poisoning Workgroup. Crit Care Med 2015; 43:1716.</a></li><li><a class="nounderline abstract_t">Duong JK, Furlong TJ, Roberts DM, et al. The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis. Drug Saf 2013; 36:733.</a></li><li><a class="nounderline abstract_t">Gan SC, Barr J, Arieff AI, Pearl RG. Biguanide-associated lactic acidosis. Case report and review of the literature. Arch Intern Med 1992; 152:2333.</a></li><li><a class="nounderline abstract_t">Heaney D, Majid A, Junor B. Bicarbonate haemodialysis as a treatment of metformin overdose. Nephrol Dial Transplant 1997; 12:1046.</a></li><li><a class="nounderline abstract_t">Teale KF, Devine A, Stewart H, Harper NJ. The management of metformin overdose. Anaesthesia 1998; 53:698.</a></li><li><a class="nounderline abstract_t">Vecchio S, Giampreti A, Petrolini VM, et al. Metformin accumulation: lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy. Clin Toxicol (Phila) 2014; 52:129.</a></li><li><a class="nounderline abstract_t">Chang CT, Chen YC, Fang JT, Huang CC. Metformin-associated lactic acidosis: case reports and literature review. J Nephrol 2002; 15:398.</a></li><li><a class="nounderline abstract_t">Khan IH, Catto GR, MacLeod AM. Severe lactic acidosis in patient receiving continuous ambulatory peritoneal dialysis. BMJ 1993; 307:1056.</a></li><li><a class="nounderline abstract_t">Chang CT, Chen YC, Fang JT, Huang CC. High anion gap metabolic acidosis in suicide: don't forget metformin intoxication--two patients' experiences. Ren Fail 2002; 24:671.</a></li><li><a class="nounderline abstract_t">Pearlman BL, Fenves AZ, Emmett M. Metformin-associated lactic acidosis. Am J Med 1996; 101:109.</a></li><li><a class="nounderline abstract_t">Hughes BW, Gray LA, Bradberry SM, et al. Metformin-associated lactic acidosis reported to the United Kingdom National Poisons Information Service (NPIS) between 2010 and 2019: a ten-year retrospective analysis. Clin Toxicol (Phila) 2023; 61:445.</a></li><li><a class="nounderline abstract_t">Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; :CD002967.</a></li><li><a class="nounderline abstract_t">Bailey CJ, Wilcock C, Day C. Effect of metformin on glucose metabolism in the splanchnic bed. Br J Pharmacol 1992; 105:1009.</a></li><li><a class="nounderline abstract_t">Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res 1994; 30:187.</a></li><li><a class="nounderline abstract_t">Chen CC, Ko Y, Chen CH, et al. Relationship between metformin use and lactic acidosis in advanced chronic kidney disease: The REMIND-TMU study. Am J Med Sci 2022; 364:575.</a></li><li><a class="nounderline abstract_t">Blumenberg A, Benabbas R, Sinert R, et al. Do Patients Die with or from Metformin-Associated Lactic Acidosis (MALA)? Systematic Review and Meta-analysis of pH and Lactate as Predictors of Mortality in MALA. J Med Toxicol 2020; 16:222.</a></li><li><a class="nounderline abstract_t">Lalau JD, Race JM. Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf 1999; 20:377.</a></li><li><a class="nounderline abstract_t">Seidowsky A, Nseir S, Houdret N, Fourrier F. Metformin-associated lactic acidosis: a prognostic and therapeutic study. Crit Care Med 2009; 37:2191.</a></li><li><a class="nounderline abstract_t">Corchia A, Wynckel A, Journet J, et al. Metformin-related lactic acidosis with acute kidney injury: results of a French observational multicenter study. Clin Toxicol (Phila) 2020; 58:375.</a></li><li><a class="nounderline abstract_t">Dell'Aglio DM, Perino LJ, Kazzi Z, et al. Acute metformin overdose: examining serum pH, lactate level, and metformin concentrations in survivors versus nonsurvivors: a systematic review of the literature. Ann Emerg Med 2009; 54:818.</a></li><li><a class="nounderline abstract_t">Lalau JD, Lacroix C, Compagnon P, et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 1995; 18:779.</a></li><li><a class="nounderline abstract_t">van Berlo-van de Laar IRF, Gedik A, van 't Riet E, et al. Identifying patients with metformin associated lactic acidosis in the emergency department. Int J Clin Pharm 2020; 42:1286.</a></li><li><a class="nounderline abstract_t">Lalau JD, Andrejak M, Morinière P, et al. Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. Int J Clin Pharmacol Ther Toxicol 1989; 27:285.</a></li><li><a class="nounderline abstract_t">Sidlak AM, Abesamis MG, Shulman JA, Marino RT. Feasibility of Intermittent Hemodialysis in Metformin Toxicity With Shock. J Emerg Med 2020; 58:749.</a></li><li><a class="nounderline abstract_t">van Berlo-van de Laar IRF, Vermeij CG, van den Elsen-Hutten M, et al. Extracorporeal treatment of metforminassociated lactic acidosis in clinical practice: a retrospective cohort study. Eur J Clin Pharmacol 2020; 76:815.</a></li><li><a class="nounderline abstract_t">Barrueto F, Meggs WJ, Barchman MJ. Clearance of metformin by hemofiltration in overdose. J Toxicol Clin Toxicol 2002; 40:177.</a></li><li><a class="nounderline abstract_t">Rifkin SI, McFarren C, Juvvadi R, Weinstein SS. Prolonged hemodialysis for severe metformin intoxication. Ren Fail 2011; 33:459.</a></li><li><a class="nounderline abstract_t">Guo PY, Storsley LJ, Finkle SN. Severe lactic acidosis treated with prolonged hemodialysis: recovery after massive overdoses of metformin. Semin Dial 2006; 19:80.</a></li><li><a class="nounderline abstract_t">Theobald J, Schneider J, Cheema N, DesLauriers C. Time to development of metformin-associated lactic acidosis. Clin Toxicol (Phila) 2020; 58:758.</a></li><li><a class="nounderline abstract_t">Harvey B, Hickman C, Hinson G, et al. Severe lactic acidosis complicating metformin overdose successfully treated with high-volume venovenous hemofiltration and aggressive alkalinization. Pediatr Crit Care Med 2005; 6:598.</a></li><li><a class="nounderline abstract_t">Lacher M, Hermanns-Clausen M, Haeffner K, et al. Severe metformin intoxication with lactic acidosis in an adolescent. Eur J Pediatr 2005; 164:362.</a></li></ol></div><div id="topicVersionRevision">Topic 296 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7700289" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hypoglycemic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2673695" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Traditional plant medicines as treatments for diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11423816" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7601013" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8569826" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Metformin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10392666" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A risk-benefit assessment of metformin in type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21241070" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical pharmacokinetics of metformin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25860205" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Extracorporeal Treatment for Metformin Poisoning: Systematic Review and Recommendations From the Extracorporeal Treatments in Poisoning Workgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23549904" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1444694" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Biguanide-associated lactic acidosis. Case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9175069" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Bicarbonate haemodialysis as a treatment of metformin overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9771180" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The management of metformin overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24283301" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Metformin accumulation: lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12243370" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Metformin-associated lactic acidosis: case reports and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8251784" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Severe lactic acidosis in patient receiving continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12380915" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : High anion gap metabolic acidosis in suicide: don't forget metformin intoxication--two patients' experiences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8686704" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Metformin-associated lactic acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37318007" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Metformin-associated lactic acidosis reported to the United Kingdom National Poisons Information Service (NPIS) between 2010 and 2019: a ten-year retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393934" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1504710" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effect of metformin on glucose metabolism in the splanchnic bed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7862618" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Re-evaluation of a biguanide, metformin: mechanism of action and tolerability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35483434" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Relationship between metformin use and lactic acidosis in advanced chronic kidney disease: The REMIND-TMU study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31907741" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Do Patients Die with or from Metformin-Associated Lactic Acidosis (MALA)? Systematic Review and Meta-analysis of pH and Lactate as Predictors of Mortality in MALA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10230584" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19487945" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Metformin-associated lactic acidosis: a prognostic and therapeutic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31387415" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Metformin-related lactic acidosis with acute kidney injury: results of a French observational multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19556031" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Acute metformin overdose: examining serum pH, lactate level, and metformin concentrations in survivors versus nonsurvivors: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7555503" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Role of metformin accumulation in metformin-associated lactic acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32960426" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Identifying patients with metformin associated lactic acidosis in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2500402" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32327212" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Feasibility of Intermittent Hemodialysis in Metformin Toxicity With Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32170333" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Extracorporeal treatment of metforminassociated lactic acidosis in clinical practice: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12126190" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clearance of metformin by hemofiltration in overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21529276" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prolonged hemodialysis for severe metformin intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16423187" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Severe lactic acidosis treated with prolonged hemodialysis: recovery after massive overdoses of metformin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31691608" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Time to development of metformin-associated lactic acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16148825" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Severe lactic acidosis complicating metformin overdose successfully treated with high-volume venovenous hemofiltration and aggressive alkalinization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15729560" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Severe metformin intoxication with lactic acidosis in an adolescent.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
